Study of the effect of the combined drug PN and HA on the regeneration of collagen fibers of the skin in an experiment
Objectives: To study the therapeutic effect of the polynucleotides and hyaluronic acid combination on the healing of skin wounds in laboratory animals.
Introduction: The scientifically justified use of drugs containing polydeoxyribonucleotide (PN /PDRN) to stimulate various regeneration links has been confirmed by repeated publications in medical literature. The pharmacological properties of PN and hyaluronic acid (HA) make it clear that, when combined, these drugs will synergistically stimulate skin healing. However, there is no information about the study of the therapeutic effect of the PN/HA combination on the healing of skin wounds yet.
Materials / method: The process of collagen fiber (CF) regeneration under the influence of a combination of polynucleotides and hyaluronic acid was studied on an experimental model of a scalp wound in 17 white mongrel rats. When analyzing the results obtained: macro- and microscopic indicators, morphometric indicators of collagen fibers in the regeneration area, the dynamics of skin CF restoration were assessed and compared in two groups: the study group, where the combined drug PN/HA was used, and in the comparison group, where a 0.9% NaCl solution was used.
Results: In PN/HA group, the dynamics of maturation of CF was ahead of that of the comparison group by an average of 7 days. In PN/HA group, restoration of skin appendages was noted in the regeneration zone by the 21rst day, a week earlier than the comparison group. During all periods of observation, CF in the area of the scalped wound were formed with an advantage in diameter and accelerated maturation, ahead of the comparison group by 7 days. Scar hypertrophy was not detected in the PN/HA group.
Conclusion: Earlier epithelialization of the wound and maturation of the collagen fiber, the normotrophic nature of scarring in the PN/HA group indicates more favorable conditions for regeneration under the influence of the combined drug PN/HA.